Smith & Nephew plc (NYSE:SNN) declared a Semi-Annual dividend on Wednesday, July 29th, Zacks reports. Stockholders of record on Friday, October 2nd will be paid a dividend of 0.278 per share by the medical equipment provider on Wednesday, October 28th. The ex-dividend date is Thursday, October 1st.
Smith & Nephew has increased its dividend payment by an average of 16.3% annually over the last three years and has increased its dividend every year for the last 1 years. Smith & Nephew has a dividend payout ratio of 58.4% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Smith & Nephew to earn $2.02 per share next year, which means the company should continue to be able to cover its $0.90 annual dividend with an expected future payout ratio of 44.6%.
NYSE:SNN traded down $0.67 during trading hours on Friday, reaching $40.25. 6,893 shares of the company traded hands, compared to its average volume of 439,660. The firm’s 50-day moving average is $40.15 and its 200-day moving average is $41.62. The stock has a market cap of $17.78 billion, a P/E ratio of 20.06, a P/E/G ratio of 6.86 and a beta of 0.56. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.06 and a quick ratio of 1.03. Smith & Nephew has a 1-year low of $26.07 and a 1-year high of $52.26.
Several analysts have recently issued reports on SNN shares. Citigroup downgraded Smith & Nephew from a “buy” rating to a “neutral” rating in a research report on Tuesday, April 14th. BofA Securities upgraded shares of Smith & Nephew from a “neutral” rating to a “buy” rating in a report on Wednesday. Cfra decreased their price target on shares of Smith & Nephew from $52.00 to $42.00 and set a “hold” rating on the stock in a research note on Thursday, May 7th. Bank of America raised shares of Smith & Nephew from a “neutral” rating to a “buy” rating in a research report on Wednesday. Finally, BNP Paribas lowered shares of Smith & Nephew from a “neutral” rating to an “underperform” rating in a research report on Friday, June 5th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $48.00.
Smith & Nephew Company Profile
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Featured Article: Compound Interest
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.